Overall outcomes of nonmyeloablative, HLA-mismatched unrelated donor BMT. (A) Cumulative incidence of count recovery. (B) Cumulative incidence of grade 2-4 acute GVHD (all grade 2) and any chronic GVHD by competing-risk analysis. (C) Cumulative incidence of grade 2-4 acute GVHD by number of mismatched HLA loci. (D) Progression-free and overall survival. ANC, absolute neutrophil count.